Article
Identification of the 5-HT1A serotonin receptor as a novel therapeutic target in a C. elegans model of Machado-Joseph disease.
Neurobiology of disease - 1 May 2021
Pereira-Sousa Joana, Ferreira-Lomba Bruna, Bellver-Sanchis Aina, Vilasboas-Campos Daniela, Fernandes Jorge H, Costa Marta D, Varney Mark A, Newman-Tancredi Adrian, Maciel Patrícia, Teixeira-Castro Andreia
Abstract excerpt
Machado-Joseph disease (MJD) or Spinocerebellar ataxia type 3 (SCA3) is a progressive neurodegenerative disorder that affects movement coordination leading to a premature death. Despite several efforts, no disease-modifying treatment is yet available for this disease. Previous studies pinpointed the modulation of serotonergic signaling, through pharmacological inhibition of the serotonin transporter SERT, as a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
